Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15671149 | 0.79 | USP2 (0.50) | ALDH1A1KMT2AANPEPATML3MBTL1 | |
| SCHEMBL611743 | 0.78 | KMT2A (0.53) | ALDH1A1KMT2AANPEPATML3MBTL1 | |
| Bromide SCHEMBL15671179 | 0.77 | KMT2A (0.50) | ALDH1A1KMT2AANPEPATML3MBTL1 | |
| SCHEMBL15236377 | 0.77 | — | — | |
| SCHEMBL7025587 | 0.76 | KMT2A (0.45) | ALDH1A1KMT2AANPEPATML3MBTL1 | |
| SCHEMBL2239461 | 0.76 | KMT2A (0.45) | ALDH1A1KMT2AANPEPATML3MBTL1 | |
| SCHEMBL8111404 | 0.76 | ANPEP (0.49) | ALDH1A1KMT2AANPEPATML3MBTL1 | |
| SCHEMBL8795715 | 0.76 | ANPEP (0.49) | ALDH1A1KMT2AANPEPATML3MBTL1 | |
| SCHEMBL13102163 | 0.76 | KMT2A (0.45) | ALDH1A1KMT2AANPEPATML3MBTL1 | |
| SCHEMBL19415318 | 0.76 | KMT2A (0.49) | ALDH1A1KMT2AANPEPATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557796-B2 | Substituted 1-oxa-2,8-diaza-spiro [4,5] dec-2-ene derivatives and related treatment methods | GRUENENTHAL GMBH (DE) | 2013-10-15 | — | — | US | claimed |
| EP-1401841-B1 | SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2005-08-24 | — | — | EP | claimed |
| US-20040192916-A1 | Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods | GRUENENTHAL GMBH (DE) | 2004-09-30 | — | — | US | claimed |
| EP-2986604-B1 | PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2017-12-20 | — | — | EP | disclosed |
| WO-2014170197-A1 | PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-23 | — | — | WO | disclosed |
| US-8557796-B2 | Substituted 1-oxa-2,8-diaza-spiro [4,5] dec-2-ene derivatives and related treatment methods | GRUENENTHAL GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| EP-1735332-B1 | AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LAB (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2046783-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080113982-A1 | AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS | ZHAO CHEN | 2008-05-15 | — | — | US | disclosed |
| US-7345034-B2 | Azacyclosteroid histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-03-18 | — | — | US | disclosed |
| US-20050245495-A1 | Azacyclosteroid histamine-3 receptor ligands | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| WO-2005100377-A1 | AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050227953-A1 | Azacyclosteroid histamine-3 receptor ligands | ABBVIE INC. | 2005-10-13 | — | — | US | disclosed |
| US-20040192916-A1 | Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods | GRUENENTHAL GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
| EP-1021411-B1 | BENZAMIDE DERIVATIVES AS THROMBIN INHIBITORS | GLAXO GROUP LTD (GB) | 2003-03-05 | — | — | EP | disclosed |
| US-6326386-B1 | ANTICOAGULANT | GLAXO GROUP LIMITED (GB) | 2001-12-04 | — | — | US | disclosed |
| EP-1021411-A1 | BENZAMIDE DERIVATIVES AS THROMBIN INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-07-26 | — | — | EP | disclosed |
| WO-1997022589-A1 | BENZAMIDE DERIVATIVES AS THROMBIN INHIBITORS | GLAXO GROUP LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
| WO-1996036595-A1 | 3,4-DISUBSTITUTED-PHENYLSULPHONAMIDES AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | GSK3B, GSK3A, MAPT | ALDH1A1 3227/4885KMT2A 705/4885ANPEP 2212/4885 |
| US-20040192916-A1 | Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods | SULT1E1, CYP4B1, CYP3A4 | ALDH1A1 412/4885KMT2A 3833/4885ANPEP 2491/4885 |
| US-20050227953-A1 | Azacyclosteroid histamine-3 receptor ligands | HRH4, HRH3, HRH2 | ALDH1A1 2714/4885KMT2A 1537/4885ANPEP 1678/4885 |
| US-20050245495-A1 | Azacyclosteroid histamine-3 receptor ligands | HRH4, HRH3, HRH2 | ALDH1A1 2714/4885KMT2A 1537/4885ANPEP 1678/4885 |
| US-20080113982-A1 | AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS | HRH4, HRH3, HRH2 | ALDH1A1 2714/4885KMT2A 1537/4885ANPEP 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.